Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alzheimer’s Imaging Agents Should Be Validated With Autopsies, Panel Says

Executive Summary

Autopsy is the gold standard for confirming a diagnosis of Alzheimer's disease and should be used as the standard of truth in studies of imaging agents hoping to gain approval for amyloid plaque detection, an FDA panel unanimously concluded

You may also be interested in...



Standards For Molecular Imaging Agents Can Vary, Panel Tells FDA

The evidence needed to show efficacy and utility of a molecular imaging agent depends on what is being scanned and what claim is being sought, FDA's Peripheral and Central Nervous System Drugs Advisory Committee advised the agency Aug. 11

Standards For Molecular Imaging Agents Can Vary, Panel Tells FDA

The evidence needed to show efficacy and utility of a molecular imaging agent depends on what is being scanned and what claim is being sought, FDA's Peripheral and Central Nervous System Drugs Advisory Committee advised the agency Aug. 11

Alzheimer’s Report To Congress: Faster FDA Approval, Orphan-Like Exclusivity

The development of biomarkers and other steps to speed FDA approval of drugs for Alzheimer's disease was recommended by the Alzheimer's Study Group as part of a 1strategic plan presented to the Senate Select Committee on Aging March 25

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS050282

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel